Emergency Filtration Products Receives Final NanoMask Risk Evaluation Report

Las Vegas, Nevada…February 29, 2008… Emergency Filtration Products, Inc. (EFP) (Other OTC:EMFP) today announced that it had received the final NanoMask Risk Evaluation Report.

As previously announced, in 2007 EFP retained internationally recognized experts in the health effects of nanomaterials to evaluate the potential health risk, if any, from use of the company’s NanoMask product. Following a thorough review of the medical evidence for nanomaterials in general and the NanoMask in particular, the experts have concluded that “the currently valid scientific evidence demonstrates the absence of unreasonable risk of illness or injury associated with the use of the NanoMask for its intended uses and conditions of use.”

“This is a major milestone in our efforts to secure FDA permission to market the NanoMask in the U.S.,” said Philip Dascher, CEO, EFP. “Working with emerging technologies, we had to originate new ways to verify the safety and effectiveness of our product, and, as a result this process has taken considerably more time than originally anticipated. However, we are intent on providing all of the information that the FDA has requested with a first-rate scientific basis, even if more time was required. “

Mr. Dascher went on to add, “We believe that this the expert Risk Evaluation Report eliminates any remaining safety questions. We are now working diligently to complete the other portions of our FDA notification and expect to file it soon.”

Safe Harbor Statement

This release may contain statements that are forward looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. EFP and ANI do not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the companies could differ significantly from such forward-looking statements.

Contact:
Philippe Niemetz
800-477-7570 or 212-344-6464
p.niemetz@panconsultants.com
Investor Relations
PAN Consultants Ltd.